September 03, 2019 Concert squares up to Pfizer in alopecia Jak bout Concert believes that high-dose data with CTP-543 will help it challenge Pfizer, but patent questions still loom large.
February 26, 2019 Xeljanz warning Jaks up safety concerns An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
September 21, 2018 Upcoming events – Phase II readouts loom for Concert and Reata Concert hopes to give Pfizer a run for its money in alopecia, while Reata looks to continue its renaissance with more Phoenix data.